Twenty Momentum Leaders Target the Next Leg Up

MarketWatch reports a cross-market study finding momentum is a persistent, universal feature of financial markets, with momentum strategies delivering profits across stocks and other asset classes. The piece then lists 20 high-momentum stocks from the Russell 3000 that produced strong trailing returns for 1/31/2025–12/31/2025: Terns Pharmaceuticals (TERN), Celcuity (CELC), Palvella Therapeutics (PVLA), Resolute Holdings Management (RHLD), Sandisk (SNDK), Inhibrx Biosciences (INBX), Zenas BioPharma (ZBIO), D-Wave Quantum (QBTS), Kodiak Sciences (KOD), Lumentum Holdings (LITE), Olema Pharmaceuticals (OLMA), EchoStar (SATS), Nuvation Bio (NUVB), Forge Global (FRGE), Praxis Precision Medicines (PRAX), Cogent Biosciences (COGT), Falcon’s Beyond Global (FBYD), Bloom Energy (BE), Taysha Gene Therapies (TSHA), and Vistance Networks (VISN). The article notes momentum’s persistence even beyond equities and emphasizes long-only momentum can still be profitable.)